Shots:
- Sandoz has launched Pyzchiva autoinjectors, a biosimilar version of Stelara (ustekinumab) in EU to treat pts (≥6yrs.; ≥60kg) with plaque PsO, PsA, Crohn’s disease & pediatric plaque PsO; commercially available in Spain, with further expansion to continue
- In Sep 2023, Sandoz & Samsung Bioepis entered into a development & commercialization agreement, granting Sandoz rights to market Pyzchiva in the Brazil, the US, the EEA, Switzerland & the UK, with Samsung handling development, registration, IP, manufacturing, & supply
- Pyzchiva is a fully human anti-IL-12/IL-23 mAb that is available in pre-filled pen as an autoinjector (45mg/0.5mL & 90mg/1mL), single-dose vials (130mg) & pre-filled syringe (45mL)
Ref: Sandoz| Image: Sandoz| Press Release
Related News:- Henlius and Sandoz Enter a Global Collaboration Agreement to Commercialize HLX13 (Biosimilar, Yervoy)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
